이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

가정 건강 관리(I-TRANSFER-HF)에서 심부전 환자의 전환 및 결과 개선: 유형 1 하이브리드 효과 - 구현 시험

2026년 11월 11일 업데이트: Weill Medical College of Cornell University

This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.

The study is interested in two questions:

  1. Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
  2. Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?

The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

The investigators' will test two hypotheses:

Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.

Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).

연구 유형

중재적

등록 (추정된)

1094

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • New York
      • New York, New York, 미국, 10021
        • 모병
        • Weill Cornell Medicine
        • 연락하다:
        • 수석 연구원:
          • Madeline R Sterling, MD, MPH, MS
      • New York, New York, 미국, 10017

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Aim 1, Inclusion Criteria:

  • Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.

Aim 1, Exclusion Criteria:

  • Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.

Aim 2, Inclusion Criteria:

- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.

Aim 2, Exclusion Criteria:

- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 건강 서비스 연구
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: I-TRANSFER-HF

This is a 1-year long intervention period when I-TRANSFER-HF is in operation.

I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US.

간섭 없음: Standard of Care (usual care)

This is a baseline period of usual care (UC) with no intervention.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
All-cause 30-day hospital readmission
기간: 30 days following post-Index HF Hospitalization

All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims

30 days following post-Index HF Hospitalization
Number of Eligible patients
기간: 12 months

Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data

12 months
Number of Eligible Patients Who Received Protocol Components
기간: 12 months

Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data

12 months
Modality of outpatient follow-up
기간: 12 months

The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data

12 months
Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation
기간: 12 months

The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data

12 months
Timeliness of Post-Hospital Outpatient Follow-Up
기간: 12 months

The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data

12 months
Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)
기간: 30 days after intervention (year of intervention)

Feasibility will be assessed through qualitative interviews with site stakeholders

30 days after intervention (year of intervention)
Feasibility of implementing I-TRANSFER-HF (Surveys)
기간: 30 days after intervention (year of intervention)

Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention.

30 days after intervention (year of intervention)

2차 결과 측정

결과 측정
측정값 설명
기간
All-cause 30-day ED visits
기간: 30 days following post-Index heart failure Hospitalization.

All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data

30 days following post-Index heart failure Hospitalization.
Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
기간: During a 12-month period (year of intervention)

Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit.

During a 12-month period (year of intervention)
Acceptability of I-TRANSFER-HF - Qualitative Interviews
기간: 30 days after intervention (year of intervention)

Acceptability will be assessed through qualitative interviews.

30 days after intervention (year of intervention)
Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey
기간: 30 days after intervention (year of intervention)

Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention.

30 days after intervention (year of intervention)
Fidelity of I-TRANSFER-HF (Participant-Completed)
기간: 30 days after intervention (year of intervention)

Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process.

30 days after intervention (year of intervention)
Fidelity of I-TRANSFER-HF (Observational Ratings)
기간: 30 days after intervention (year of intervention)

Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process.

30 days after intervention (year of intervention)
Adaptation of I-TRANSFER-HF
기간: 30 days after intervention (year of intervention)

Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period.

30 days after intervention (year of intervention)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Madeline R Sterling, MD, MPH, MS, Weill Medical College of Cornell University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 11월 1일

기본 완료 (추정된)

2027년 7월 1일

연구 완료 (추정된)

2028년 7월 1일

연구 등록 날짜

최초 제출

2023년 10월 31일

QC 기준을 충족하는 최초 제출

2023년 10월 31일

처음 게시됨 (실제)

2023년 11월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 23-06026204
  • R01HL169312 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .